Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closure

Canadian Cancer Trials Group IND.186 -- Phase I/II Study of Sorafenib (BAY 43-9006) in Combination with Low Dose Ara-C (Cytarabine) in Elderly Patients with AML or High-Risk MDS -- was closed to accrual 10 December 2009.

http://www.ctg.queensu.ca/trials/ind/i186/186.html